CervoMed Inc. Files 8-K: Other Events & Financials
Ticker: CRVO · Form: 8-K · Filed: Oct 16, 2024 · CIK: 1053691
| Field | Detail |
|---|---|
| Company | Cervomed Inc. (CRVO) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, corporate-events
TL;DR
CervoMed filed an 8-K on 10/15/24 for 'Other Events' and financials - details pending.
AI Summary
CervoMed Inc. filed an 8-K on October 15, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about the nature of these events or financial statements, only that they were reported on this date. The company, formerly known as Diffusion Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Boston, Massachusetts.
Why It Matters
This 8-K filing indicates CervoMed Inc. has reported significant events and financial updates, which could impact investor understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: medium — The filing is an 8-K reporting 'Other Events' and financial statements, but lacks specific details, creating uncertainty about the nature and impact of these disclosures.
Key Numbers
- 001-37942 — Commission File Number (Identifies the company's filing with the SEC)
- 30-0645032 — I.R.S. Employer Identification No. (Company's tax identification number)
Key Players & Entities
- CervoMed Inc. (company) — Registrant
- Diffusion Pharmaceuticals Inc. (company) — Former company name
- October 15, 2024 (date) — Date of earliest event reported
- 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (location) — Principal executive offices address
FAQ
What specific 'Other Events' are being reported by CervoMed Inc. in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond listing it as an item of disclosure.
What are the key details of the 'Financial Statements and Exhibits' mentioned in the 8-K?
The filing lists 'Financial Statements and Exhibits' as an item but does not provide any specific financial figures or details within the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 15, 2024.
What is CervoMed Inc.'s principal executive office address?
CervoMed Inc.'s principal executive offices are located at 20 Park Plaza, Suite 424, Boston, Massachusetts 02116.
What was CervoMed Inc. formerly known as?
CervoMed Inc. was formerly known as Diffusion Pharmaceuticals Inc.
Filing Stats: 435 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-10-16 08:00:12
Key Financial Figures
- $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
Filing Documents
- crvo20241015_8k.htm (8-K) — 29KB
- ex_732854.htm (EX-99.1) — 16KB
- logosmlr.jpg (GRAPHIC) — 4KB
- 0001437749-24-031300.txt ( ) — 184KB
- crvo-20241015.xsd (EX-101.SCH) — 3KB
- crvo-20241015_def.xml (EX-101.DEF) — 11KB
- crvo-20241015_lab.xml (EX-101.LAB) — 15KB
- crvo-20241015_pre.xml (EX-101.PRE) — 11KB
- crvo20241015_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On October 15, 2024, CervoMed Inc. (the "Company") issued a press release announcing the last patient, last visit in its RewinD-LB Trial, a Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued October 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 16, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel 3